Table 1.
Liposomal formulations designed for nose-to-brain delivery of hydrophilic drugs.
| Composition | Particle Size | Zeta Potential | Drug (MW) |
Target Disease | In Vivo | Dosing Position | Dosing Volume | Ref. |
|---|---|---|---|---|---|---|---|---|
| DOPC:CHOL:SA | 149 nm | +30 mV | GDNF (15,100) |
Parkinson’s Disease | SD rat | supine | 25 μL | [64,65] |
| DOPC:CHOL:SA | 299 nm | +19 mV | ovalbumin (43,000) |
SD rat | supine | 25 μL | [66] | |
| HSPC:CHOL | 128 nm | −15 mV | bFGF (16,500) |
ischemic stroke | SD rat | supine | ~30 μL | [67] |
| EPC:CHOL:DSPE-PEG | 112 nm | +3 mV | H102 peptide (1,289) |
AD | SD rat | 40 μL | [68] | |
| soyPC:DHAHAB | 142 nm | +6 mV | 2-PAM (173) | Organoph-osphorous poisoning | Wistar rat | [69] | ||
| EPC:CHOL | 166 nm | +11 mV | rivastigmine tartrate (400) |
AD | SD rat | supine | ~80 μL | [70] |
| EPC:CHOL | 40 nm | −48 mV | ferric ammonium citrate (262) | iron deficiency | SD rat | supine | 45 μL | [71] |
| soyPC:CHOL (30:0.2) |
112 nm | +49 mV | galanthamine hydrobromide (368) | AD | SD rat | prone | 40 μL | [72] |
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); cholesterol (CHOL); N-(Carbonyl-methoxypolyethyleneglycol 2000)-1, 2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG); egg-phosphatidylcholine (EPC); stearylamine (SA); glial-derived neutotrophic factor (GDNF); dihexadecylmethylhydroxyethylammonium bromide (DHAHAB); hydrogenated soy phosphatidylcholine (HSPC); basic fibroblast growh factor (bFGF); pyridine-2-aldoxime methochloride (2-PAM).